ArticleInfection and immunity2005
Selection of protective epitopes for Brucella melitensis by DNA vaccination.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 76 citations in OpenAlex.
- Immune Efficacy of a Vaccine Candidate Based on Binding Protein 26 (BP26) from Brucella melitensis Encapsulated in Niosome Nanoparticles Against Brucellosis.Pharmaceutical research · 2026Article
- Protective Immunity of a Novel Multi-Epitope Vaccine Encoding OMP31, TF, BLS, SOD, BP26, and L9 Against Brucella spp. InfectionIranian biomedical journal · 2025Article
- A comprehensive comparison of DNA and RNA vaccines.Advanced drug delivery reviews · 2024Review
- Proteome-Wide Screening of Potential Vaccine Targets againstVaccines · 2023Article
- Trigger Factor in Association with the ClpP1P2 Heterocomplex ofACS omega · 2021Article
- Binding of Brucella protein, Bp26, to select extracellular matrix molecules.BMC molecular and cell biology · 2019Article
- Streptococcus pneumoniae Cell Wall-Localized Trigger Factor Elicits a Protective Immune Response and Contributes to Bacterial Adhesion to the Host.Scientific reports · 2019Article
- Identification of Cross-Protective Potential Antigens against PathogenicJournal of immunology research · 2018Article
- Development and trial of vaccines againstJournal of veterinary science · 2017Review
- Immune reactivity of sera obtained from brucellosis patients and vaccinated-rabbits to a fusion protein from Brucella melitensis.Iranian journal of basic medical sciences · 2015Article
- In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate.Iranian journal of basic medical sciences · 2014Article
- Brucella melitensis T cell epitope recognition in humans with brucellosis in Peru.Infection and immunity · 2014Article
- Sustained and differential antibody responses to virulence proteins of Brucella melitensis during acute and chronic infections in human brucellosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013Article
- Immune reactivity of Brucella melitensis-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins.Iranian journal of microbiology · 2013Article
- Progress inFrontiers in biology · 2013Article
- Immunogenicity and protective potential of a bacterially expressed recombinant dihydrolipoamide succinyltransferase (rE2o) of Brucella abortus in BALB/c mice.World journal of microbiology & biotechnology · 2012Article
- Serial kinetics of the antibody response against the complete Brucella melitensis ORFeome in focal vertebral brucellosis.Journal of clinical microbiology · 2012Article
- Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development.Frontiers in cellular and infection microbiology · 2012Article
- Characterization of periplasmic protein BP26 epitopes of Brucella melitensis reacting with murine monoclonal and sheep antibodies.PloS one · 2012Article
- Systems biology approach predicts antibody signature associated with Brucella melitensis infection in humans.Journal of proteome research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The Brucella melitensis 16M genome was examined for proteins in excess of 100 amino acids and for immunogenicity-associated genes. One subset of 32 annotated genes or open reading frames was identified, and each of these were cloned into the eukaryotic vector pcDNA3.1. Purified recombinant plasmids were used to intramuscularly (i.m.) immunize BALB/c mice. After challenge with B. melitensis 16M strain, two protective antigens were found: the periplasmic protein, bp26, and the chaperone protein, trigger factor (TF). Protective efficacy was confirmed with DNA vaccines for these two B. melitensis proteins and, when combined, protection against wild-type challenge was significantly enhanced. Both proteins were found to be immunogenic since elevated serum immunoglobulin G (IgG) antibodies without a specific IgG subclass bias were induced subsequent to i.m. DNA immunization. Antigen-restimulation assays revealed that bp26 and TF stimulated gamma interferon and only bp26 induced interleukin-4 (IL-4), IL-5, and IL-6 cytokines as measured by cytokine enzyme-linked immunospot assay. These collective results suggest that both bp26 and TF are excellent candidates for use in future vaccination studies against brucellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.